CRRTF (Crescita Therapeutics) Cyclically Adjusted Book per Share: $0.90 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRRTF Crescita Therapeutics Inc CRRTF
22 GF Score
Price $0.56
GF Value $0.50
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Cyclically Adjusted Book per Share?

Crescita Therapeutics CRRTF 22 Cyclically Adjusted Book per Share is $0.90 as of Mar. 2026. GuruFocus rates CRRTF with a GF Score™ of 22/100 and a GF Value™ of $0.50 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Crescita Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $0.565. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.90 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Crescita Therapeutics's average Cyclically Adjusted Book Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-03), Crescita Therapeutics's current stock price is $0.5587. Crescita Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.90. Crescita Therapeutics's Cyclically Adjusted PB Ratio of today is 0.62.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Crescita Therapeutics was 0.64. The lowest was 0.35. And the median was 0.42.


Crescita Therapeutics  (OTCPK:CRRTF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Crescita Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.5587/0.90
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Crescita Therapeutics was 0.64. The lowest was 0.35. And the median was 0.42.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Crescita Therapeutics Cyclically Adjusted Book per Share Related Terms


Crescita Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Cyclically Adjusted Book per Share Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.97 0.91

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.60 0.89 0.91 0.90

CRRTF vs ZTS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Cyclically Adjusted PB Ratio falls into.


CRRTF
22GF Score
Crescita Therapeutics Inc CRRTF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Crescita Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.565/132.2623*132.2623
=0.565

Current CPI (Mar. 2026) = 132.2623.

Crescita Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 1.776 102.002 2.303
201609 1.562 101.765 2.030
201612 1.240 101.449 1.617
201703 1.086 102.634 1.400
201706 1.119 103.029 1.437
201709 1.184 103.345 1.515
201712 0.701 103.345 0.897
201803 0.599 105.004 0.754
201806 0.568 105.557 0.712
201809 0.587 105.636 0.735
201812 0.673 105.399 0.845
201903 0.689 106.979 0.852
201906 0.776 107.690 0.953
201909 0.782 107.611 0.961
201912 0.773 107.769 0.949
202003 0.715 107.927 0.876
202006 0.627 108.401 0.765
202009 0.798 108.164 0.976
202012 0.799 108.559 0.973
202103 0.800 110.298 0.959
202106 0.796 111.720 0.942
202109 0.731 112.905 0.856
202112 0.764 113.774 0.888
202203 0.757 117.646 0.851
202206 0.750 120.806 0.821
202209 0.731 120.648 0.801
202212 0.764 120.964 0.835
202303 0.749 122.702 0.807
202306 0.762 124.203 0.811
202309 0.707 125.230 0.747
202312 0.703 125.072 0.743
202403 0.686 126.258 0.719
202406 0.647 127.522 0.671
202409 0.618 127.285 0.642
202412 0.582 127.364 0.604
202503 0.545 129.181 0.558
202506 0.605 129.892 0.616
202509 0.631 130.287 0.641
202512 0.607 130.366 0.616
202603 0.565 132.262 0.565

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.90 mean?
Crescita Therapeutics (CRRTF) has a Cyclically Adjusted Book per Share of $0.90 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Cyclically Adjusted Book per Share too high?
Crescita Therapeutics' current Cyclically Adjusted Book per Share is $0.90. Overall, Crescita Therapeutics has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Cyclically Adjusted Book per Share compare to ZTS?
Crescita Therapeutics' Cyclically Adjusted Book per Share of $0.90 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Cyclically Adjusted Book per Share is $0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (CRRTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $0.90. Crescita Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Crescita Therapeutics (CRRTF), the current Cyclically Adjusted Book per Share is $0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (CRRTF) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of $0.56 is trading 11.7% above its estimated GF Value™ of $0.50. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for CRRTF:

  • Cyclically Adjusted Book per Share: $0.90
  • GF Value™: $0.50 vs. price of $0.56 (11.7% above fair value)
  • GF Score™: 22/100 with 5 warning signs

No single metric tells the full story. See the CRRTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
22GF Score

Get the complete analysis for CRRTF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.50
GF Value